Profund Advisors LLC Boosts Stake in Arcus Biosciences, Inc. $RCUS

Profund Advisors LLC raised its holdings in Arcus Biosciences, Inc. (NYSE:RCUS) by 125.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 39,639 shares of the company’s stock after purchasing an additional 22,048 shares during the quarter. Profund Advisors LLC’s holdings in Arcus Biosciences were worth $945,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. raised its position in Arcus Biosciences by 13,547.6% in the third quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock valued at $39,000 after purchasing an additional 2,845 shares during the period. GAMMA Investing LLC raised its holdings in shares of Arcus Biosciences by 17.5% in the 4th quarter. GAMMA Investing LLC now owns 3,230 shares of the company’s stock valued at $77,000 after buying an additional 482 shares during the period. Abich Financial Wealth Management LLC purchased a new stake in shares of Arcus Biosciences in the 3rd quarter valued at $69,000. Bayforest Capital Ltd purchased a new stake in shares of Arcus Biosciences in the 4th quarter valued at $190,000. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Arcus Biosciences by 184.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,449 shares of the company’s stock valued at $69,000 after buying an additional 5,476 shares during the period. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Price Performance

Shares of NYSE RCUS opened at $23.82 on Friday. The stock’s 50-day moving average is $23.36 and its two-hundred day moving average is $22.50. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.04 and a quick ratio of 4.04. Arcus Biosciences, Inc. has a 1-year low of $7.91 and a 1-year high of $28.72. The company has a market cap of $3.00 billion, a price-to-earnings ratio of -7.49 and a beta of 0.87.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.10). Arcus Biosciences had a negative return on equity of 68.97% and a negative net margin of 156.36%.The company had revenue of $17.00 million for the quarter, compared to analysts’ expectations of $29.49 million. During the same quarter last year, the company earned ($1.14) EPS. Arcus Biosciences’s revenue for the quarter was down 39.3% compared to the same quarter last year. Analysts forecast that Arcus Biosciences, Inc. will post -3.54 EPS for the current fiscal year.

Insiders Place Their Bets

In other Arcus Biosciences news, CFO Robert C. Goeltz II sold 7,763 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $25.63, for a total transaction of $198,965.69. Following the sale, the chief financial officer owned 84,161 shares in the company, valued at $2,157,046.43. This represents a 8.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.60% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on RCUS shares. Leerink Partners set a $47.00 price objective on Arcus Biosciences in a report on Monday, April 20th. Wall Street Zen downgraded Arcus Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcus Biosciences in a report on Monday, April 20th. HC Wainwright reiterated a “buy” rating and issued a $32.00 price objective on shares of Arcus Biosciences in a report on Monday, March 2nd. Finally, The Goldman Sachs Group boosted their price objective on Arcus Biosciences from $30.00 to $34.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $33.89.

Arcus Biosciences Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.